Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies

Next Previous
X
Search
Trial Profile

Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Brain metastases; Breast cancer; Carcinoma; Malignant melanoma; Meningeal carcinomatosis; Neuroendocrine carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pituitary cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2027.
    • 08 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2026.
    • 01 Jul 2023 Results published in the Nature Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top